ライフサイエンスコーパス: drug evaluation

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ZAN is suitable for application in nicotinic drug evaluation.

2 or the development of therapeutic agents and drug evaluation.

3 one of these Nf1 GEM models for preclinical drug evaluation.

4 te significantly to preclinical and clinical drug evaluation.

5 inding to develop a platform for preclinical drug evaluation.

6 nd demonstrate the potential of hiPSC-CMs in drug evaluation.

7 shed compendia, American Medical Association Drug Evaluations (AMA-DE), United States Pharmacopoeia D

8 technique with a strong potential for use in drug evaluation and development.

9 ed and validated according to the Center for Drug Evaluation and Research (CDER) guidelines.

10 The Center for Drug Evaluation and Research (CDER) within the US Food a

11 US Food and Drug Administration's Center for Drug Evaluation and Research and MEDLINE for initial app

12 Within the Center for Drug Evaluation and Research this review team for ophtha

13 , 2004, at a joint meeting of the Center for Drug Evaluation and Research's Psychopharmacologic Drugs

14 American Medical Association Drug Evaluations and USP-DI subsequently ceased publicat

15 de the development of therapeutic agents and drug evaluation by providing molecular level insight int

16 y in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) trial demonstrated that empiri

17 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) nuclear substudy compared the

18 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) study, which provided optimal

19 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial reignited the controvers

20 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, some patients with stab

21 e Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, which will be the large

22 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.

23 s Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE]; NCT00007657).

24 s Utilizing Revascularization and Aggressive Drug Evaluation) diabetes subgroup, (n = 766 of 2,287),

25 Third, we used FASS-LTP for drug evaluation in human synaptosomes.

26 Italian Agency of Drug Evaluation, Istituto Giannina Gaslini (Genoa, Italy

27 ve anticancer compounds, current preclinical drug evaluations largely fail to satisfy the demand.

28 s Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657) (Bypass Angioplasty Revasc

29 s Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657).

30 s Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657).

31 -nAChRs and the radioligand was suitable for drug evaluation studies.

32 For preclinical antiviral drug evaluation, the GMP version of the myristoylated pr

33 s Utilizing Revascularization and Aggressive Drug Evaluation) trial according to the presence (+) or

34 s Utilizing Revascularization and Aggressive Drug Evaluation) trial and its effect on risk factors.

35 s Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic st

36 s Utilizing Revascularization and Aggressive Drug Evaluation) trial found similar CV event rates betw

37 s Utilizing Revascularization and Aggressive druG Evaluation) trial randomized 2,287 patients to opti

38 s Utilizing Revascularization and Aggressive Drug Evaluation) trial showed that coronary intervention

39 s Utilizing Revascularization and Aggressive DruG Evaluation) trial.

40 ed outcomes are increasingly incorporated in drug evaluation trials.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。